Commercial Pfizer protects $6.4bn heart disease blockbuster from generics, for now Pharmaceutical TechnologyPfizer's Vyndamax will be free from generics competition until 2031 in a boost to the company's revenue streams.CardiovascularRead full story pharminent April 29, 2026 (Last updated: April 30, 2026) Pharmaceutical Technology Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Chiesi to buy KalVista in $1.9B deal for rare disease drugNext: Avalyn, in pursuit of better lung drugs, banks $300M in an IPO Related Stories Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026 Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
